Forest plot analysis of OS related factors showed that the benefit of SBRT combined with lenvatinib exceeded that of lenvatinib monotherapy in the patients of male, age ≥ 55 or < 55, HBV infection, Child–Pugh class A, ECOG score 0 or 1, number of tumors > 3, tumor size ≥ 5 cm and < 10 cm, PVTT Vp1-2 or Vp3-4, ALBI grade 2, and AFP ≤ 200 (Fig. 4). Here, AFP is linked to neoplasm.